Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
暂无分享,去创建一个
T. Ashizawa | A. Iizuka | E. Tanaka | Ryota Kondou | H. Miyata | Chie Maeda | T. Sugino | K. Yamaguchi | T. Ando | Y. Ishikawa | Mamoru Ito | Y. Akiyama | C. Maeda | Emiko Tanaka
[1] D. Y. Lin,et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors , 2008, Proceedings of the National Academy of Sciences.
[2] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[3] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[4] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[5] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[6] T. Komori,et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma , 2013, Cancer science.
[7] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[8] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[9] A. Abdel-Magid. Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections. , 2015, ACS medicinal chemistry letters.
[10] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[11] G. Freeman,et al. Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.
[12] Lei Liu,et al. Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. , 2015, Angewandte Chemie.
[13] Jedd D. Wolchok,et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.
[14] K. Zak,et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.
[15] T. Ashizawa,et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse , 2016, Clinical Cancer Research.
[16] Axel Hoos,et al. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.
[17] K. Zak,et al. Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015) , 2016, Expert opinion on therapeutic patents.
[18] T. Ashizawa,et al. Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. , 2016, International journal of oncology.
[19] Chenzhong Liao,et al. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. , 2016, Drug discovery today.
[20] T. Holak,et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. , 2017, Journal of medicinal chemistry.
[21] L. Skalniak,et al. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. , 2017, Angewandte Chemie.
[22] T. Ashizawa,et al. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. , 2017, Immunology letters.
[23] L. Skalniak,et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells , 2017, Oncotarget.
[24] K. Zak,et al. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. , 2017, Structure.
[25] P. Buchwald,et al. Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. , 2018, Current topics in medicinal chemistry.
[26] Katarzyna Guzik,et al. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018) , 2018, Expert opinion on therapeutic patents.
[27] PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules. , 2018, Current pharmaceutical design.
[28] S. Patil,et al. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction. , 2018, Chemical & pharmaceutical bulletin.
[29] M. Ramachandra,et al. Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways , 2018, BioDrugs.
[30] Mamoru Ito,et al. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses , 2017, Cellular & Molecular Immunology.
[31] F. Feng,et al. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy? , 2019, European journal of medicinal chemistry.
[32] M. Ramachandra,et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy , 2019, Molecular Cancer Therapeutics.
[33] T. Holak,et al. Design, synthesis, evaluation and structural studies of C2-symmetric small molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) protein-protein interaction. , 2019, Journal of medicinal chemistry.